GLP-1 treatment basics: what actually matters vs. filler advice

What did @drathaizafloressaab actually say?

Honestly, not much that we can work with. The transcript provided is largely incoherent, consisting of repeated filler phrases like "the first one is the first one" and "the second one is the second one." The caption promises three fundamentals for a "well-done, healthy treatment with great results" in the GLP-1 space, but the actual spoken content doesn't deliver those three things in any legible way.

This matters because 271,900 people watched this video. Whatever was communicated visually, through on-screen text, or in portions of the audio not captured in transcription may have reached a large audience with specific claims about GLP-1 therapy. Without a reliable transcript, we're fact-checking a ghost. What we can do is address what those three fundamentals commonly are in GLP-1 content from Brazilian medical creators, and whether the general framing holds up to scrutiny.

Does the science back this up?

The premise, that GLP-1 receptor agonist therapy requires specific foundational pillars to be effective and safe, is well-supported. The evidence is not ambiguous on this point. GLP-1 therapy without behavioral and clinical scaffolding produces worse outcomes than GLP-1 therapy with it.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced mean weight loss of 14.9% over 68 weeks, but that was alongside a reduced-calorie diet and increased physical activity. Participants who discontinued the drug in the STEP 4 extension regained two-thirds of their lost weight within a year (Rubino et al., 2021, JAMA), which tells you that the drug alone is not the full picture. Similarly, tirzepatide data from SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed impressive results under structured lifestyle intervention conditions, not in isolation.

So if the creator's three fundamentals include nutrition, movement, and medical supervision, the science does support that framing. The problem is we can't confirm that's what was said.

What did they get wrong (or right)?

We can't fairly assign errors to a transcript that is essentially unintelligible. That said, the framing deserves a mild flag on its own. Calling something "fundamental" for a "well-done treatment" positions the creator as a treatment authority, and in Brazil, prescribing guidance from social media, even from credentialed physicians, sits in a regulatory gray zone under CFM (Conselho Federal de Medicina) guidelines on telemedicine and digital health communication.

What the creator appears to get right, based on the video's category and caption framing, is the concept that GLP-1 therapy is not a standalone intervention. That's accurate. No serious clinical protocol treats semaglutide or tirzepatide as a single-lever solution. The American Diabetes Association's Standards of Care (2024) and obesity medicine guidelines from AACE both position pharmacotherapy as one component of a multimodal approach.

What's harder to credit or criticize is the specificity. "Three things" is a clean content format, but it can flatten clinical nuance. A patient with type 2 diabetes on liraglutide has different fundamentals than someone using semaglutide for weight management without metabolic comorbidities. One-size framing is a real risk in this content category.

What should you actually know?

GLP-1 receptor agonists are genuinely effective medications with a growing evidence base. They are also not simple. The drugs in this class, semaglutide, tirzepatide, liraglutide, and newer agents like retatrutide, work through different receptor mechanisms with different side effect profiles, titration schedules, and clinical considerations. What counts as a "fundamental" for one patient may be irrelevant or even contraindicated for another.

A few things the evidence is clear on: protein intake matters during GLP-1-assisted weight loss to preserve lean mass (Cava et al., 2017, Advances in Nutrition). Resistance training alongside GLP-1 therapy significantly improves body composition outcomes compared to cardio alone (Lundgren et al., 2024, Nature Medicine). And consistent medical follow-up, including monitoring for pancreatitis risk, thyroid changes, and gastrointestinal tolerability, is not optional.

If you're considering or currently using a GLP-1 medication, the most important thing is working with a licensed prescriber who can individualize your protocol, not following a three-step social media framework, however well-intentioned.